Outcome and management of hepatitis C in liver transplant recipients.
Hepatitis C virus (HCV)-related cirrhosis is the leading indication for liver transplantation. Reinfection of the allograft with HCV is universal in all patients with pretransplantation viremia, and leads to histologically proven hepatitis in 50%-80% of these patients. Recent data have demonstrated significantly higher mortality among HCV-positive liver transplant recipients. For this subgroup of patients, retransplantation remains highly controversial. As current antiviral therapy is limited in efficacy and tolerability, an improved understanding of those patients at greatest risk of developing serious HCV-induced graft injury is necessary to optimize treatment.
Chan
Susan E
SE
Division of Gastroenterology/Hepatology, Portland Veterans Affairs Medical Center, Portland, Oregon 97207, USA.
Rosen
Hugo R
HR
D000998:Antiviral Agents / Q000627:therapeutic use; D016174:Hepacivirus; D006526:Hepatitis C / Q000188:drug therapy / Q000209:etiology*; D006801:Humans; D008103:Liver Cirrhosis / Q000188:drug therapy / Q000821:virology; D016031:Liver Transplantation / Q000009:adverse effects*; D012008:Recurrence; D012307:Risk Factors; D014184:Transplantation, Homologous / Q000009:adverse effects*
D000998:Antiviral Agents